Is NOVO NORDISK A S (NVO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 76.4% / 30% | 15.7% / 30% | 52.0% / 30% | 0.41% / 5% | ✗ NOT HALAL |
| DJIM | 76.4% / 33% | 15.7% / 33% | 52.0% / 33% | 0.41% / 5% | ✗ NOT HALAL |
| MSCI | 24.1% / 33% | 5.0% / 33% | 16.4% / 33% | 0.41% / 5% | ✓ HALAL |
| S&P | 76.4% / 33% | 15.7% / 33% | 52.0% / 33% | 0.41% / 5% | ✗ NOT HALAL |
| FTSE | 24.1% / 33% | 5.0% / 33% | 16.4% / 50% | 0.41% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.4% | |
| Operating Margin | 44.5% | |
| Net Margin | 33.1% | |
| Return on Equity (ROE) | 60.7% | |
| Return on Assets (ROA) | 17.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $119.1B |
| Free Cash Flow | $29.0B |
| Total Debt | $131.0B |
| Debt-to-Equity | 67.5 |
| Current Ratio | 0.8 |
| Total Assets | $542.9B |
Price & Trading
| Last Close | $36.40 |
| 50-Day MA | $46.07 |
| 200-Day MA | $53.95 |
| Avg Volume | 24.2M |
| Beta | 0.3 |
|
52-Week Range
$35.85
| |
About NOVO NORDISK A S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NOVO NORDISK A S (NVO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NOVO NORDISK A S is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NOVO NORDISK A S's debt ratio?
NOVO NORDISK A S's debt ratio is 76.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.1%.
What are NOVO NORDISK A S's key financial metrics?
NOVO NORDISK A S has a market capitalization of $161.2B, trailing P/E ratio of 10.1, and revenue of $309.1B. The company maintains a gross margin of 82.4% and a net margin of 33.1%. Return on equity stands at 60.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.